These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30048016)

  • 41. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
    Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
    Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib.
    Sansone V; Tovoli F; Casadei-Gardini A; Di Costanzo GG; Magini G; Sacco R; Pressiani T; Trevisani F; Rimini M; Tortora R; Nardi E; Ielasi L; Piscaglia F; Granito A
    Clin Transl Gastroenterol; 2021 Jan; 12(1):e00286. PubMed ID: 33443944
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Azemoto R; Shinozaki M; Yoshikawa M; Yokosuka O
    PLoS One; 2015; 10(4):e0125244. PubMed ID: 25919025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
    Li L; Gou CY; Li JY; Achakzai R; Li XH
    Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials.
    Li X; Dong M; Lin Q; Chen ZH; Ma XK; Xing YF; Wan XB; Wen JY; Wei L; Chen J; Wu XY
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):86-92. PubMed ID: 23279888
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neoadjuvant radiotherapy provided survival benefit compared to adjuvant radiotherapy for hepatocellular carcinoma.
    Lin H; Li X; Liu Y; Hu Y
    ANZ J Surg; 2018 Oct; 88(10):E718-E724. PubMed ID: 29399938
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group.
    Vitale A; Lai Q; Farinati F; Bucci L; Giannini EG; Napoli L; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Cabibbo G; Virdone R; Marra F; Felder M; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Missale G; Masotto A; Nardone G; Colecchia A; Bernardi M; Trevisani F; Pawlik TM;
    J Gastrointest Surg; 2018 May; 22(5):859-871. PubMed ID: 29352441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Impact of Serosal Invasion on Prognosis after Curative Hepatectomy for Hepatocellular Carcinoma: Invasion to Adjacent Organs and Rupture of Tumor Were Crucial Tumor-Related Prognostic Factors Needed for Survival.
    Kato Y; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Uesaka K
    Dig Surg; 2018; 35(2):155-163. PubMed ID: 28787731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of split completeness on future liver remnant hypertrophy in associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in hepatocellular carcinoma: Complete-ALPPS versus partial-ALPPS.
    Chan ACY; Chok K; Dai JWC; Lo CM
    Surgery; 2017 Feb; 161(2):357-364. PubMed ID: 27596751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma.
    Okuwaki Y; Nakazawa T; Kokubu S; Hidaka H; Tanaka Y; Takada J; Watanabe M; Shibuya A; Minamino T; Saigenji K
    Am J Gastroenterol; 2009 Nov; 104(11):2747-53. PubMed ID: 19603009
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.
    Chen L; Ni CF; Chen SX; Cao JM; Zhu HD; Guo JH; Zhu GY; Zhong BY; Ding W; He SC; Deng G; Teng GJ
    J Vasc Interv Radiol; 2016 Sep; 27(9):1288-1297. PubMed ID: 27013402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Laparoscopic ablation therapies or hepatic resection in cirrhotic patients with small hepatocellular carcinoma.
    Santambrogio R; Bruno S; Kluger MD; Costa M; Salceda J; Belli A; Laurent A; Barabino M; Opocher E; Azoulay D; Cherqui D
    Dig Liver Dis; 2016 Feb; 48(2):189-96. PubMed ID: 26675381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.
    Ueno S; Sakoda M; Kubo F; Hiwatashi K; Tateno T; Baba Y; Hasegawa S; Tsubouchi H;
    J Hepatobiliary Pancreat Surg; 2009; 16(3):359-66. PubMed ID: 19300896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee PC; Loong CC; Chiang JH; Huo TI; Lee SD
    Cancer; 2010 Jun; 116(12):3006-14. PubMed ID: 20564406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Cancer of the Liver Italian Program (CLIP) score: validation of a new prognostic system for hepatocellular carcinoma.
    Takanishi DM; Severino R; Wong LL
    Hawaii Med J; 2007 Aug; 66(8):209-12. PubMed ID: 17941373
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the prognostic powers of various tumor status grading scales in patients with hepatocellular carcinoma.
    Seo YS; Kim YJ; Um SH; Yoo H; Lee JW; Kim YS; Jeen YT; Chun HJ; Kim CD; Ryu HS
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1267-75. PubMed ID: 18637054
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma.
    Ni XC; Yi Y; Fu YP; He HW; Cai XY; Wang JX; Zhou J; Cheng YF; Jin JJ; Fan J; Qiu SJ
    Medicine (Baltimore); 2015 Sep; 94(36):e1486. PubMed ID: 26356714
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study.
    Pang Q; Zhou L; Qu K; Cui RX; Jin H; Liu HC
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):60-70. PubMed ID: 29189392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area.
    Lee JH; Kim HY; Kim YJ; Yoon JH; Chung JW; Lee HS
    J Gastroenterol Hepatol; 2015 Apr; 30(4):696-705. PubMed ID: 25250761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.